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OBJECTIVES: To determine whether the previously described trend of improving 
mortality in people with coronavirus disease 2019 in critical care during the first 
wave was maintained, plateaued, or reversed during the second wave in United 
Kingdom, when B117 became the dominant strain.
DESIGN: National retrospective cohort study.
SETTING: All English hospital trusts (i.e., groups of hospitals functioning as single 
operational units), reporting critical care admissions (high dependency unit and ICU) 
to the Coronavirus Disease 2019 Hospitalization in England Surveillance System.
PATIENTS: A total of 49,862 (34,336 high dependency unit and 15,526 ICU) 
patients admitted between March 1, 2020, and January 31, 2021 (inclusive).
INTERVENTIONS: Not applicable.
MEASUREMENTS AND MAIN RESULTS: The primary outcome was inhospi-
tal 28-day mortality by calendar month of admission, from March 2020 to January 
2021. Unadjusted mortality was estimated, and Cox proportional hazard models 
were used to estimate adjusted mortality, controlling for age, sex, ethnicity, major 
comorbidities, social deprivation, geographic location, and operational strain (using 
bed occupancy as a proxy). Mortality fell to trough levels in June 2020 (ICU: 22.5% 
[95% CI, 18.2–27.4], high dependency unit: 8.0% [95% CI, 6.4–9.6]) but then 
subsequently increased up to January 2021: (ICU: 30.6% [95% CI, 29.0–32.2] 
and high dependency unit, 16.2% [95% CI, 15.3–17.1]). Comparing patients 
admitted during June–September 2020 with those admitted during December 
2020–January 2021, the adjusted mortality was 59% (CI range, 39–82) higher in 
high dependency unit and 88% (CI range, 62–118) higher in ICU for the later pe-
riod. This increased mortality was seen in all subgroups including those under 65.
CONCLUSIONS: There was a marked deterioration in outcomes for patients 
admitted to critical care at the peak of the second wave of coronavirus disease 
2019 in United Kingdom (December 2020–January 2021), compared with the 
post-first-wave period (June 2020–September 2020). The deterioration was in-
dependent of recorded patient characteristics and occupancy levels. Further 
research is required to determine to what extent this deterioration reflects the 
impact of the B117 variant of concern.
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National data from the United Kingdom (1, 2), as well as internationally (3), suggest that the mortality risk for patients admitted to critical care settings with coronavirus disease 2019 (COVID-19) appears to have declined 
over time. This improvement is consistent with a growing evidence base on how to 
John M. Dennis, PhD1
Andrew P. McGovern, MD Res1
Nicholas J. Thomas, MRCP
Harrison Wilde, BSc2
Sebastian J. Vollmer, PhD2,3
Bilal A. Mateen, MBBS3,4
Trends in 28-Day Mortality of Critical Care 
Patients With Coronavirus Disease 2019 in 
United Kingdom: A National Cohort Study, 




2     www.ccmjournal.org XXX 2021 • Volume XX • Number XXX
best manage patients with COVID-19, such as changes 
in ventilation strategy (4), identification of several effec-
tive pharmacological interventions (5, 6), and extending 
mechanical ventilation bed capacity to meet demand (7). 
However, near the end of 2020, new variants emerged, 
associated with increased rates of transmissibility (8, 9). 
These new variants in combination with the accompany-
ing operational strain on health systems (10) raised con-
cerns that mortality rates might again rise. In this study, 
we sought to assess whether the aforementioned trend 
of improving survival rates that we previously described 
in people with severe COVID-19 requiring critical care 
(high dependency unit [HDU] or ICU) management (1) 




Data pertaining to all adult COVID-19–specific crit-
ical care (HDU) and ICU) admissions across United 
Kingdom, between March 1, 2020, and January 31, 2021, 
were extracted from the COVID-19 Hospitalization 
in England Surveillance System (CHESS)—a surveil-
lance dataset containing information on all individuals 
with diagnostic test confirmed or clinically presumed 
COVID-19 managed in HDU or ICU (11). Follow-up 
data were available until March 5, 2021. Daily trust-
level bed occupancy data (from April 1, 2020, to 
January 31, 2021, March 2020 data were not available) 
were extracted from the daily situation reports submit-
ted by each trust to the national regulator (12).
Individual-Level Critical Care Data
The following characteristics were extracted for each 
individual from CHESS: age, sex, ethnicity, first seg-
ment of postcode (used to identify the relevant indices 
of multiple deprivation for the corresponding areas in 
United Kingdom), admitting hospital trust (each trust 
may comprise more than one hospital), and recorded 
comorbidities (obesity, diabetes, asthma, other chronic 
respiratory disease, chronic heart disease, hyperten-
sion, immunosuppression due to disease or treatment, 
chronic neurologic disease, chronic renal disease, and 
chronic liver disease). We coded ethnicity as: White, 
Asian, Black, mixed, and other, categorized hospital 
centers by region: London, East of United Kingdom, 
Midlands, North East and Yorkshire, North West, 
South East, and South West, and recorded comor-
bidities as binary No/Yes variables. Missing data were 
assumed to represent the absence of comorbidity and 
the appropriateness of this imputation procedure, and 
alternatives are explored elsewhere (13).
Occupancy Data
Trust-level occupancy of HDU beds and beds compat-
ible with mechanical ventilation (as a proxy for ICU 
strain [7]) were linked to each individual’s record based 
on their admitting trust. Occupancy was defined as a 
percentage, relative to capacity during the baseline pre-
pandemic period (January–March 2020). We linked in-
formation from daily situation reports on prepandemic 
(January–March 2020) number of beds compatible with 
mechanical ventilation, the number of HDU beds, the 
proportion of beds compatible with mechanical ven-
tilation occupied on each day of the study period, and 
each trust’s geographical region. Linkage was carried out 
based on the trust that an individual was admitted to and 
the date of admission in CHESS; patients in CHESS were 
matched via their admission date to the relevant occu-
pancy information from the corresponding date in the 
daily situation reports. The full preparation and linking 
of these data to CHESS are reported elsewhere (10).
Eligibility and Study Cohorts
Patients 18–99 yr were eligible, but pregnant women 
(n = 430) were excluded. Subsequently, two cohorts 
were defined, the first comprising all people admit-
ted to HDU but not ICU, and the second including all 
people admitted to ICU.
Statistical Analysis
The primary outcome was inhospital all-cause mor-
tality in the 28 days after hospital admission for HDU 
admitted patients and 28 days after intensive care ad-
mission for ICU patients. Patients discharged alive or 
transferred prior to 28 days were assumed to be alive at 
28 days. We estimated absolute (unadjusted) mortality 
for each calendar month (March 2020 to January 2021 
inclusive) as the proportions of deaths/total number of 
admissions, overall and for subgroups defined by age 
(less than/greater than or equal to 65) and recorded 
comorbidity (none/one or more). Adjusted mortality 
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by calendar month of admission (categorical variable) 
was estimated using Cox proportional hazards mod-
els, adjusting for age (three-knot nonlinear restricted 
cubic spline), sex, ethnicity, recorded comorbidities, 
deprivation index, and geographical region, with pro-
portional hazards assumptions tested. For the ICU co-
hort, we additionally adjusted for the number of days 
from hospital to ICU admission (to capture possible 
changes in admission policy over time, e.g., if there 
were delays in admitting patients to ICU in months 
when concern over hospital capacity was greatest). 
As sensitivity analysis, we repeated the overall model 
adjusting for occupancy and with hospital trust in-
cluded as a random effect. To further explore mor-
tality during the second wave in United Kingdom, 
we grouped admissions in the months of December 
2020–January 2021 (peak second wave), early second 
wave (October–November 2020), post-first wave (June 
2020–September 2020), and first wave (March–April 
2020) and compared adjusted (Cox models) mortality 
across periods, overall and for age and comorbidity-
defined subgroups. Analyses were conducted with R 
(Version 3.6.2; R Foundation for Statistical Computing, 
Vienna, Austria [14]), including the following pack-
ages: survival, rms and coxme.
RESULTS
A total of 49,862 (34,336 HDU and 15,526 ICU) patients 
were included across 110 hospital trusts (sFlowchart, 
http://links.lww.com/CCM/G595); 6,765 (19.7%) HDU 
and 5,119 (32.9%) ICU patients died within 28 days of 
admission. Mean follow-up was 24 days (sd, 8 d) for 
HDU patients and 20 days (sd, 10 d) for ICU patients. 
Recorded characteristics are reported in sTable 1 (http://
links.lww.com/CCM/G595); patients admitted to ICU 
were older (mean 70 [sd, 17] vs 59 [sd, 13]), were more 
commonly male (68.8% vs 53.5%), and had greater re-
corded major comorbidity burden (43.6% vs 39.6% with 
at least one major comorbidity). The number of patients 
in critical care peaked in January 2021 (Fig. 1A).
Twenty-eight-day inhospital mortality decreased 
from March 2020 to June 2020: ICU March 40.5% (95% 
CI, 38.6–42.5), June 22.5% (95% CI, 18.2–27.4); HDU 
March 28.0% (95% CI, 26.8–29.3), June 8.0% (95% 
CI, 6.5–9.6), before increasing up to January 2021: 
ICU 30.6% (95% CI, 29.0–32.2), HDU 16.2% (95% CI, 
15.3–17.1) (Fig. 1A). Differences persisted following 
adjustment for recorded characteristics (Fig. 1B).
For patients admitted in December 2020–January 
2021 (peak second wave) compared with June–
September 2020 (post-first wave), adjusted mortality 
Figure 1. Mortality risk and number of admissions by month from 
March 2020 to January 2021. A, Number of patients in critical 
care and 28-d inhospital mortality, by calendar month. Underlying 
numerical data are provided in sTable 2 (http://links.lww.com/CCM/
G595). B, Adjusted mortality by calendar month. Estimates are hazard 
ratios representing the difference in mortality relative to May 2020, 
chosen as the month after the peak of the first wave, but prior to the 
Randomized Evaluation of COVID-19 Therapy (RECOVERY) press 
release demonstrating the efficacy of dexamethasone (5). Note: 
adjustments are for age (three knot restricted cubic spline), sex, 
ethnicity, recorded comorbidities, deprivation index, and geographical 
region. Bars represent 95% CIs. HDU = high dependency unit.
Dennis et al
4     www.ccmjournal.org XXX 2021 • Volume XX • Number XXX
was 88% (CI, 62–118) higher in ICU and 59% (CI, 39–82) 
higher in HDU (sTable 2, http://links.lww.com/CCM/
G595). The mortality increase was greater in the 
peak second wave than that in the early second wave 
(October–November 2020), but never reached the 
mortality level of the first wave (March–April 2020) 
(sTable 3, http://links.lww.com/CCM/G595). Adjusted 
mortality differences by time period were similar 
across subgroups defined by age and comorbidity, in-
cluding patients under 65 (Table 1; sFig. 1 and sTable 3, 
http://links.lww.com/CCM/G595).
Results were concordant with the primary analysis 
when adjusting for occupancy level on the day of ad-
mission as an additional covariate (available for 28,414 
TABLE 1. 
Overall and Subgroup Analysis to Compare Outcomes of Patients Admitted During June–
September 2020 (Post-First-Wave Period) Versus December 2020–January 2021 (Peak of 
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(95% CI)c
High dependency unit
Overall 268/2,628 (10.2%) 1,689/10,285 
(16.4%)






Patients < 65 yr 21/923 (2.3%) 129/3,515 
(3.7%)
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HR = hazard ratio.
a No diabetes, chronic respiratory disease, heart disease, renal disease, liver disease, neurologic disease, or immunosuppession.
b Adjusted for age (three knot restricted cubic spline), sex, ethnicity, recorded comorbidities, deprivation index, and geographical region.
c Adjusted for occupancy, age (three knot restricted cubic spline), sex, ethnicity, recorded comorbidities, deprivation index, and geographical 
region. Occupancy available only for patient subset (high dependency unit overall, n = 28,414; aged less than 65, n = 9,119; aged greater 
than or equal to 65, n = 19,295; no major recorded comorbidity, n = 17,207; major comorbidity, n = 11,207; ICU: overall, n = 12,099; aged 
less than 65, n = 7,665; aged greater than or equal to 65, n = 4,434; no major recorded comorbidity, n = 6,876; comorbidity, n = 5,223).
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HDU and 12,099 ICU patients), and with admitting 
trust modeled as an additional random effect (Table 1; 
and sFig. 2, http://links.lww.com/CCM/G595].
DISCUSSION
Our study of nearly 50,000 critical care patients illus-
trates a marked deterioration in outcomes for patients 
admitted at the peak of the second wave of COVID-
19 pandemic in the United Kingdom (December 
2020–January 2021) compared with the post-first-
wave period (June–September 2020). In absolute 
terms when comparing the peak of the second-wave 
to the post-first-wave period (June–September 2020), 
mortality was 8.8% higher in ICU and 6.2% higher in 
HDU. Notably, despite this increase, peak second-wave 
mortality never reached that seen during the first wave.
The overall trend we observed in CHESS is con-
cordant with those reported by the United Kingdom’s 
national critical care audit Intensive Care National 
Audit & Research Centre (ICNARC) that collected 
critical care data via a separate mechanism (15). Both 
analyses show 28-day mortality has increased since the 
post-first-wave period while never reaching the first-
wave peak of March–April 2020, the period prior to 
the Randomized, Embedded, Multi-factorial, Adaptive 
Platform Trial for Community-Acquired Pneumonia 
(REMAP-CAP) and Randomized Evaluation of 
COVID-19 Therapy (RECOVERY) trial results dem-
onstrating efficacious therapies (6, 7). A novel finding 
of our study is that the deterioration in patient out-
comes in recent months has been observed in younger 
as well as older adults, and in people with and without 
major comorbidity. These findings highlight the im-
portance of continuing population-level disease sup-
pression strategies until younger, healthier people have 
been vaccinated as well as the at-risk and elderly.
Further research is needed to understand the causes 
of the mortality time trends observed. This is likely mul-
tifactorial, with potential influences including: changes 
in the severity of critical care patients, health system 
operational strain, and the emergence of the new B117 
variants of concern (VOCs) in the United Kingdom, 
which was first sequenced in October 2020 (16) and be-
came the dominant strain in individuals who tested pos-
itive for COVID-19 by November 2020. Of note, when 
comparing post-B117 (December–January 2021) to pre-
B117 (June–September 2020) time periods, we show a 
59% (95% CI, 39–82) higher mortality in HDU and 88% 
(95% CI, 62–108) higher mortality in ICU, which is con-
cordant with the reported 64% (95% CI, 32–104) higher 
mortality associated with the B117 variant in the United 
Kingdom compared with other strains of severe acute 
respiratory syndrome coronavirus 2 (8). Although we 
lacked data on severity of illness at admission to critical 
care, congruence of our results with ICNARC analysis, 
which includes these physiologic data, suggests residual 
confounding by disease severity is unlikely to explain 
our findings (15). In terms of precritical care treatment, 
dexamethasone was consistently and widely used to 
treat people with COVID-19 presenting to hospital in 
the United Kingdom over both the summer period and 
second wave. This consistent treatment pattern means 
that patients with severe treatment-refractory infection 
requiring critical care are likely to be comparable across 
the two time periods, although we lacked information 
on treatment and total COVID-19 hospitalizations to 
interrogate this further. Notably, ours is the first analysis 
to adjust for operational strain and demonstrate it did 
not explain mortality time trends, although this may not 
be a comprehensive proxy, as “unsafe” occupancy lev-
els reflect a small minority of all operational issues that 
hospitals reported during the pandemic (B. A. Mateen 
et al, unpublished observations, 2021), and data for sev-
eral thousand people admitted during March 2020 are 
missing, as these data was not available for that time 
period (see sFlowchart, http://links.lww.com/CCM/
G595). The other major operational risk factor that is yet 
to have its impact characterized during the pandemic is 
that of staff absence and burnout, an important question 
for future research.
CONCLUSIONS
The second wave of COVID-19 in United Kingdom saw 
critical care mortality rates deteriorate over December 
2020–January 2021 to levels markedly higher than 
those observed in the post-first-wave period of June–
September 2020. Further research is needed to de-
termine to what extent this deterioration reflects the 
impact of the B117 VOC.
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